These somewhat disappointing results may reflect the poor brain penetration of Tocilizumab as well as the schizophrenic patient population evaluated, as greatest elevations in IL-6 levels are generally found in first-episode and acute relapsed subjects, rather than in chronically treated schizophrenia patients—as were evaluated in the Tocilizumab trial. This evidence concerns the gene IL6 and schizophrenia.